Previous close | 1.4100 |
Open | 1.4200 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's range | 1.3700 - 1.4699 |
52-week range | 1.3300 - 12.8000 |
Volume | |
Avg. volume | 1,083,198 |
Market cap | 20.171M |
Beta (5Y monthly) | -0.36 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
SOUTH SAN FRANCISCO, Calif., March 07, 2024--CERo Therapeutics Holdings, Inc., (NASDAQ:CERO) ("CERo") an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms today announced the publication in Clinical Cancer Research, a journal of the American Association for Cancer Research, a paper titled "Therapeutic Targeting of TIM-4-L With Engineered T Cells for Acute Myeloid Leukemia." The paper details preclinical stu
OAKLAND, Calif. & SOUTH SAN FRANCISCO, Calif., February 14, 2024--Phoenix Biotech Acquisition Corp. (NASDAQ:PBAX) ("PBAX") and CERo Therapeutics, Inc., an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms ("CERo") today announced that their previously announced business combination has closed, resulting in CERo becoming a publicly-traded company. In connection with the consummation of the business combinati